|
Characteristic
|
L-AmB (n = 60)
|
CAS (n = 60)
|
|---|
|
No. of patients (%)
|
|---|
|
Gender
| | |
|
male
|
33 (55.0)
|
38 (63.3)
|
|
female
|
27 (45.0)
|
22 (36.7)
|
|
Age group
| | |
|
< 6 yr.
|
20 (33.3)
|
17 (28.3)
|
|
6 - 11 yr.
|
24 (40.0)
|
20 (33.3)
|
|
12 - < 18 yr.
|
16 (26.7)
|
23 (38.3)
|
|
Donor
| | |
|
MUD
|
20 (33.3)
|
19 (31.7)
|
|
MMUD
|
4 (6.7)
|
1 (1.7)
|
|
MMFD
|
29 (48.3)
|
23 (38.3)
|
|
MFD
|
7 (11.7)
|
17 (28.3)
|
|
Primary diagnosis
| | |
|
ALL
|
18 (30.0)
|
17 (28.3)
|
|
AML
|
7 (11.7)
|
1 (1.7)
|
|
JMML
|
3 (5.0)
|
2 (3.3)
|
|
CML
|
3 (5.0)
|
-
|
|
MDS
|
6 (10.0)
|
5 (8.3)
|
|
NHL
|
1 (1.7)
|
3 (5.0)
|
|
Solid tumors
|
9 (15.0)
|
10 (16.7)
|
|
Aplastic anemia
|
1 (1.7)
|
10 (16.7)
|
|
Neurometabolic diseases
|
5 (8.3)
|
5 (8.3)
|
|
Immunodeficiency
|
4 (6.7)
|
7 (11.7)
|
|
Chediak-Higashi-syndrome
|
2 (3.3)
|
-
|
|
Morbus Kostmann
|
1 (1.7)
|
-
|
|
Graft-versus-Host Disease
| | |
|
Grade I
|
22 (36.7)
|
24 (40.0)
|
|
Grade II
|
4 (6.7)
|
5 (8.3)
|
|
Grade III
|
2 (3.3)
|
2 (3.3)
|
|
Grade IV
|
2 (3.3)
|
2 (3.3)
|
|
Chronic limited
|
1 (1.7)
|
3 (5.3)
|
|
Chronic extensive
|
1 (1.7)
|
1 (1.7)
|
- Abbreviation: ALL, acute lymphoblastic leukemia; AML acute myelogenous leukemia; CAS, caspofungin; CML, chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia; L-AmB, liposomal amphotericin B; MDS, myelodysplastic syndromes; MFD, matched family donor; MMFD, mismatched family donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; NHL, Non-Hodgkin lymphoma.
